Ibex Investors’s Veracyte VCYT Stock Holding History

Ibex Investors’s Portfolio VCYT Stock Details VCYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-8,053	Closed	-$230	–	106
2019 Q2	$230	Buy	+8,053	New	+$201K	0.02%	63

Other funds holding VCYT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Ibex Investors's VCYT Position: Q3 2019 in Review

Ibex Investors sold out of Veracyte (VCYT) in Q3 2019, closing a stake of 8,053 shares — an estimated $230 sold.

Ibex Investors first reported a position in VCYT in Q2 2019 and held it in 1 quarter. The position peaked at $230 in Q2 2019. 187 funds tracked by Wall St. Rank hold VCYT as of Q3 2019.

Ibex Investors reported no remaining Veracyte position as of Q3 2019 after selling out during the quarter.
Ibex Investors sold 8,053 Veracyte shares in Q3 2019, an estimated $230.
Ibex Investors first reported a position in Veracyte in Q2 2019 and held it in 1 quarter.
Ibex Investors's Veracyte position peaked at $230 in Q2 2019.
187 funds tracked by Wall St. Rank held Veracyte as of Q3 2019.

Based on Ibex Investors's 13F filing for Q3 2019, filed 1 Nov 2019.